EGFR and melanoma: We have recently reported that combination of lapatinib with a γ-secretase inhibitor (GSI), to concurrently inhibit the ERBB and Notch pathways, promotes melanoma regression, whereas the use of either inhibitor alone can only delay tumor growth [3].